Survival Analysis of Triple Negative Breast Cancer Patients Treated with Anthracycline based Chemotherapy in Central Part of India | Chapter 16 | Issues and Developments in Medicine and Medical Research Vol. 1

 TNBC (triple negative breast cancer) is more common in premenopausal and younger women. TNBC are biologically aggressive tumours that have not reacted well to hormonal or targeted therapy, despite evidence that they do. The goal of this trial was to see how effective anthracycline-based adjuvant treatment was in triple negative breast cancer patients.

The goal of this study was to see how triple negative breast cancer patients fared after receiving anthracycline-based chemotherapy.

Materials and Procedures: Between January 2016 and March 2017, a retrospective analysis of 100 post-operative patients with histopathologically verified ductal Carcinoma Breast reported to a tertiary care centre. All of the patients were triple negative, according to immunohistochemistry and fluorescence in situ hybridization. The patients were to receive six rounds of anthracycine-based combination adjuvant chemotherapy. The data was analysed with SPSS 20 and a survival analysis was done.

The total number of patients in this trial was 100. After treatment, 18 patients (18%) defaulted, 29 patients (29%) were lost during future follow-ups, 49 patients (49%) had disease free survival (DFS), and four patients (4%) survived with bone metastases. The three-year overall survival (OS) time was 18.6 months, with a median survival time of 18 months, a disease-free survival time of 7.8 months, and a median survival time of 18 months.

TNBC is a challenge for both patients and professionals because of its dismal prognosis and limited therapeutic choices. TNBC patients who receive adjuvant anthracycline-based combination chemotherapy had a better long-term prognosis.

Author(S) Details

Dheerendra Kumar Sachan
Department of Radiation Oncology, Shrimant Rajmata Vijayaraje Scindia Medical College, Shivpuri, MP, India.

Abhishek Shrivastava
Department of Radiation Oncology, Atal Bihari Vajpayee Government Medical College Vidisha, MP, India.

Ruchita Sachan
Department of Pathology, Ram Manohar Lohia Institute of Medical Science, Lucknow, UP, India.

Varsha Mandloi
Department of Radiation Oncology, Pravara Rural Hospital and Medical College, Loni, Maharashtra, India.

View Book:- https://stm.bookpi.org/IDMMR-V1/article/view/5165